$AGLE News
Last published 2y ago
- 2y agoAGLEAeglea BioTherapeutics Announces Name Change to Spyre Therapeutics, Appoints CEO and Additional Directors, and Expands Leadership Team to Develop Next-Generation Therapeutic Combinations for the Treatment of IBDPR NewswireAeglea BioTherapeutics, Inc. (NASDAQ: AGLE) (the "Company" or "Spyre"), a development-stage biotechnology company, today announced its name change to ...
- 2y agoAGLEAeglea BioTherapeutics Announces Grants of Inducement AwardsPR NewswireAeglea BioTherapeutics, Inc. ("Aeglea") (NASDAQ: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to...
- 3y agoAGLEAeglea BioTherapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate UpdatePR NewswireAeglea BioTherapeutics, Inc. ("Aeglea" or the "Company") (NASDAQ:AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with...
- 3y agoAGLEAeglea BioTherapeutics Announces Grants of Inducement AwardsPR NewswireAeglea BioTherapeutics, Inc. ("Aeglea") (NASDAQ: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to...
- 3y agoAGLEAeglea BioTherapeutics to Participate in Upcoming November Investor ConferencesPR NewswireAeglea BioTherapeutics, Inc. ("Aeglea") (Nasdaq: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to...
- 3y agoAGLEAeglea BioTherapeutics Announces Grants of Inducement AwardsPR NewswireWALTHAM, Mass., Oct. 2, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (NASDAQ:AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the
- 3y agoAGLEAeglea BioTherapeutics to Participate in Upcoming September ConferencePR NewswireWALTHAM, Mass., Sept. 14, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (NASDAQ:AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the
- 3y agoAGLEAeglea BioTherapeutics Announces Reverse Stock SplitPR NewswireWALTHAM, Mass., Sept. 7, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (NASDAQ:AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the
- 3y agoAGLEARQTAeglea BioTherapeutics Expands Executive Leadership Team with Appointment of Industry Veterans Scott Burrows and Heidy Abreu King-JonesPR NewswireScott Burrows, former Arcutis Biotherapeutics CFO, assumes role as Chief Financial Officer Heidy Abreu King-Jones, former Provention Bio CLO & Corporate Secretary, assumes role as Chief Legal Officer &
- 3y agoAGLEAeglea BioTherapeutics Reports Second Quarter 2023 Financial ResultsPR NewswireAcquisition of Spyre's assets and concurrent oversubscribed $210.0 million private investment positions the company to advance a potentially best-in-class inflammatory bowel disease (IBD) portfolio, including α4b7
- 3y agoAGLEAeglea BioTherapeutics Announces Sale of Pegzilarginase to Immedica PharmaPR NewswireGlobal rights to pegzilarginase in development for Arginase 1 Deficiency sold to Immedica Pharma for $15 million upfront cash proceeds and up to $100 million of contingent milestone payments Marketing Authorisation
- 3y agoAGLEAeglea BioTherapeutics Announces Grant of Inducement AwardsPR NewswireAUSTIN, Texas and WALTHAM, Mass., June 23, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (NASDAQ:AGLE) today announced that, in connection with the acquisition of Spyre Therapeutics, Inc.
- 3y agoAGLEMRTXONCYPOAI+1Increased Funding for Pancreatic Cancer Trials & Treatments Rising along with Demand for New DrugsPR NewswireFinancialNewsMedia.com News Commentary PALM BEACH, Fla., June 22, 2023 /PRNewswire/ -- Pancreatic cancer is one of the leading causes of cancer death globally. The increasing incidence of this cancer across the U.S. and
- 3y agoAGLEAeglea BioTherapeutics Announces Acquisition of Spyre TherapeuticsPR NewswireAcquisition of Spyre and concurrent oversubscribed $210 million private investment positions the company to advance a leading inflammatory bowel disease (IBD) portfolio Spyre, the second spinout from Paragon
- 3y agoAGLEAeglea BioTherapeutics Reports First Quarter 2023 Financial ResultsPR Newswire$39.8 million of cash and cash equivalents, marketable securities, and restricted cash as of March 31, 2023 AUSTIN, Texas, May 11, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) today announced financial
- 3y agoAGLEAeglea BioTherapeutics Announces Interim Results from Ongoing Phase 1/2 Clinical Trial of Pegtarviliase for the Treatment of Classical Homocystinuria and Begins Process to Explore Strategic AlternativesPR NewswireResults from Cohorts 1 and 2 Showed a Dose-Dependent Reduction in Total Homocysteine Levels Results from Cohort 3 Indicated Additional Dose Exploration and Data from Longer Treatment Duration May be Needed AUSTIN,
- 3y agoAGLEAeglea BioTherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR NewswireAUSTIN, Texas, March 17, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare
- 3y agoAGLEAeglea BioTherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Program UpdatesPR NewswireJeffrey Goldberg, experienced biotech executive, appointed president and CEO; further strengthened senior management team with appointments of chief medical officer and chief product officer $57.3 million of cash, cash
- 3y agoAGLEA Study of Safety of Weekly Subcutaneous Pegzilarginase in Subjects With Arginase 1 Deficiency - NCT05676853ClinicalTrials.govTreatment emergent adverse events
- 3y agoAGLEAeglea BioTherapeutics Announces Update to Corporate Structure to Increase Operational EfficiencyPR NewswireStreamlining of organization to focus on near-term deliverables for pegtarviliase in Homocystinuria and long-term value creation Cortney Caudill, M.B.A., has been promoted to the newly created role of chief product
- 3y agoAGLEAeglea BioTherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)PR NewswireAUSTIN, Texas, Dec. 2, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare
- 3y agoAGLEAeglea BioTherapeutics Appoints Jeffrey M. Goldberg as Chief Executive OfficerPR NewswireAUSTIN, Texas, Nov. 30, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare
- 3y agoAGLEAeglea BioTherapeutics Appoints Linda Neuman, M.D., M.B.A, to Chief Medical OfficerPR NewswireAUSTIN, Texas, Nov. 15, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare
- 4y agoAGLEAeglea BioTherapeutics Reports Third Quarter 2022 Financial Results and Provides Program UpdatesPR NewswireInterim Clinical Data from Phase 1/2 Trial of Pegtarviliase Expected in Fourth Quarter of 2022; Currently Dosing Cohort 3 at 1.35 mg/kg MAA for Pegzilarginase for the Treatment of Arginase 1 Deficiency Accepted for
- 4y agoAGLEAeglea BioTherapeutics Hosting Key Opinion Leader Webinar on Classical Homocystinuria and Pegtarviliase's Potential Role in TreatmentPR NewswireEvent to be Held Thursday, October 27th at 10 AM ET AUSTIN, Texas, Oct. 19, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human
- 4y agoAGLEAeglea BioTherapeutics Provides Clinical Progress and Regulatory Update for Homocystinuria ProgramPR NewswireAUSTIN, Texas, Oct. 4, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced
- 4y agoAGLEAeglea BioTherapeutics Announces Presentations at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2022PR NewswireAUSTIN, Texas, Aug. 29, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced oral
- 4y agoAGLEAeglea BioTherapeutics Announces Leadership Transition and Corporate RestructuringPR NewswirePrioritizing Resources and Focus on AGLE-177 and the Completion of the Ongoing Phase 1/2 Trial in Homocystinuria with Interim Clinical Data Expected in Q4 of 2022 Dr. Anthony Quinn, President, CEO and Board Member, has Stepped Down from His Current Po
- 4y agoAGLEAeglea BioTherapeutics Announces European Medicines Agency Validation of Marketing Authorization Application for Pegzilarginase for the Treatment of Arginase 1 DeficiencyPR NewswireAUSTIN, Texas, Aug. 18, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced that
- 4y agoAGLEAeglea BioTherapeutics Reports Second Quarter 2022 Financial Results and Provides Program UpdatesPR NewswireCohort 2 Completed in Phase 1/2 Trial of AGLE-177; Data Expected in Fourth Quarter of 2022 Actively Engaged with FDA to Identify Potential Paths Forward for Pegzilarginase Gross Proceeds of $45 Million from May 2022 Registered Direct Offering Extend
- 4y agoAGLEAeglea BioTherapeutics Receives Refusal to File Letter from FDA for Pegzilarginase for the Treatment of Arginase 1 DeficiencyPR NewswireAUSTIN, Texas, June 2, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced that i
- 4y agoAGLEAeglea BioTherapeutics Announces $45 Million Registered Direct Offering Priced at a Premium to MarketPR NewswireAUSTIN, Texas, May 5, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announce
- 4y agoAGLEAeglea BioTherapeutics Reports First Quarter 2022 Financial Results and Provides Program UpdatesPR NewswirePegzilarginase BLA submitted to the FDA; if approved, pegzilarginase would be the first FDA-approved treatment for Arginase 1 Deficiency Additional PEACE data supporting potential efficacy of pegzilarginase presented at SIMD Enrollment continues in
- 4y agoAGLEATNMBCDABDSX+1Thinking about buying stock in Actinium Pharmaceuticals, BioCardia, Veru, Biodesix, or Aeglea Bio Therapeutics?PR NewswireNEW YORK, April 12, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ATNM, BCDA, VERU, BDSX, and AGLE.
- 4y agoAGLEAeglea BioTherapeutics Submits BLA to FDA for Pegzilarginase for the Treatment of Arginase 1 DeficiencyPR NewswireBLA submission provides FDA with all pegzilarginase program data to review in detail; Aeglea looks forward to working collaboratively with the FDA on next steps in the review process If approved, pegzilarginase would be the first FDA-approved treatment
- 4y agoAGLEAeglea BioTherapeutics Presents Additional Data from PEACE Phase 3 Study of Pegzilarginase for the Treatment of Arginase 1 Deficiency at SIMDPR NewswireAUSTIN, Texas, April 11, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today shared additio
- 4y agoAGLEAeglea BioTherapeutics to Participate in the Needham Virtual Healthcare Conferences in April 2022PR NewswireAUSTIN, Texas, April 6, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced its p
- 4y agoAGLEAeglea BioTherapeutics Announces Presentation of Additional Data from PEACE Phase 3 Study of Pegzilarginase for the Treatment of Arginase 1 Deficiency at the Society for Inherited Metabolic Disorders Annual MeetingPR NewswireAUSTIN, Texas, March 29, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced post
- 4y agoAGLEAeglea BioTherapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Program UpdatesPR NewswireAUSTIN, Texas, March 8, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced
- 4y agoAGLEAeglea BioTherapeutics Withdraws Public OfferingPR NewswireAUSTIN, Texas, Feb. 10, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, announced t
- 4y agoAGLEAeglea BioTherapeutics Announces Proposed Public OfferingPR NewswireAUSTIN, Texas, Feb. 9, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced a
- 4y agoAGLEAeglea BioTherapeutics Announces Upcoming KOL and Patient Caregiver Webinar on Arginase 1 DeficiencyPR NewswireAUSTIN, Texas, Jan. 25, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced that
- 4y agoAGLEAeglea BioTherapeutics to Participate in Two Investor Conferences in January 2022PR NewswireAUSTIN, Texas, Jan. 5, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced its pa
- 4y agoAGLEALZNGRTXSELB+1Thinking about buying stock in Galera Therapeutics, Terminix Global, Aeglea Bio Therapeutics, Alzamend Neuro, or Selecta Biosciences?PR NewswireNEW YORK, Dec. 14, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GRTX, TMX, AGLE, ALZN, and SELB.
- 4y agoAGLEA Multiple Ascending Dose Study of ACN00177 in Subjects With CBS Deficiency - NCT05154890ClinicalTrials.govIncidence of treatment-emergent adverse events, Pharmacokinetic Profile of IV ACN00177, Pharmacokinetic Profile of Subcutaneous ACN00177, (and 2 more...)
- 4y agoACETAGLEARDXFULC+1Thinking about buying stock in Adicet Bio, GCP Applied Technologies, Aeglea Bio Therapeutics, Fulcrum Therapeutics, or Ardelyx?PR NewswireNEW YORK, Dec. 6, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACET, GCP, AGLE, FULC, and ARDX. T
- 4y agoAGLEAeglea BioTherapeutics Announces Achievement of Primary Endpoint in Phase 3 Study of Pegzilarginase in Patients with Arginase 1 DeficiencyPR NewswireAUSTIN, Texas, Dec. 6, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced t
- 4y agoAGLEAeglea BioTherapeutics to Host Conference Call to Report Phase 3 Topline Results of Pegzilarginase in Patients with Arginase 1 DeficiencyPR NewswireAUSTIN, Texas, Dec. 5, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced t
- 4y agoAGLEAeglea BioTherapeutics Appoints Hunter C. Smith to Board of DirectorsPR NewswireAUSTIN, Texas, Nov. 16, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced
- 5y agoAGLEAeglea BioTherapeutics Reports Third Quarter 2021 Financial Results and Corporate HighlightsPR NewswireAUSTIN, Texas, Nov. 4, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced